Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative trial of Xeomin versus Botox in children with spastic equine/equinovarus foot due to cerebral palsy
2016-005049-21Phase 2
- Sponsor
- Merz Pharma
- Start
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of botulinum toxin type A in cerebral palsy (CP) (2 arms), sponsored by Merz Pharma. Primary endpoint: Change in gastrocnemius spasticity (modified Ashworth scale).
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on 2016-005049-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005049-21.